06.26.18
Kramer Laboratories, Inc., a Coral Gables, FL-based marketer of over-the-counter foot care and specialty cough products, has acquired the Nizoral anti-dandruff shampoo brand sold in North America and Latin America, from Janssen Pharmaceutica NV, a member of the Johnson & Johnson family of companies.
Kramer is a portfolio company of Avista Capital Partners, a healthcare-focused private equity firm, and Dana Holdings, a consumer healthcare-focused private investment group.
"We are delighted to add Nizoral, an iconic OTC brand, to the Kramer portfolio. With over a 25 year history, Nizoral is one of the most widely-recognized and highly-trusted brands in therapeutic hair care,” said Rick Kornhauser, CEO of Kramer. “This acquisition also significantly enhances our financial profile, adding meaningful scale, growth and profitability to our company. We look forward to building upon Nizoral's strong brand heritage and continuing to grow the brand through investment and brand support."
David Burgstahler, president and co-managing partner of Avista called the purchase a “transformative acquisition for Kramer, one that not only adds an exceptional brand to the portfolio, but also establishes Kramer as a leading OTC consumer healthcare platform of scale. We are excited about Kramer's future prospects and are committed to supporting the company's continued development and expansion."
Kramer is a portfolio company of Avista Capital Partners, a healthcare-focused private equity firm, and Dana Holdings, a consumer healthcare-focused private investment group.
"We are delighted to add Nizoral, an iconic OTC brand, to the Kramer portfolio. With over a 25 year history, Nizoral is one of the most widely-recognized and highly-trusted brands in therapeutic hair care,” said Rick Kornhauser, CEO of Kramer. “This acquisition also significantly enhances our financial profile, adding meaningful scale, growth and profitability to our company. We look forward to building upon Nizoral's strong brand heritage and continuing to grow the brand through investment and brand support."
David Burgstahler, president and co-managing partner of Avista called the purchase a “transformative acquisition for Kramer, one that not only adds an exceptional brand to the portfolio, but also establishes Kramer as a leading OTC consumer healthcare platform of scale. We are excited about Kramer's future prospects and are committed to supporting the company's continued development and expansion."